NM_000251.3:c.89C>T
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 1P and 1B. PP3BP6
The NM_000251.3(MSH2):c.89C>T(p.Pro30Leu) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000111 in 1,447,798 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000251.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 exomes AF: 0.00000455 AC: 1AN: 219710Hom.: 0 AF XY: 0.00000835 AC XY: 1AN XY: 119784
GnomAD4 exome AF: 0.0000111 AC: 16AN: 1447798Hom.: 0 Cov.: 31 AF XY: 0.00000974 AC XY: 7AN XY: 719044
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Lynch syndrome 1 Uncertain:2Benign:1
This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 27363726]. -
- -
- -
not provided Uncertain:2
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Published functional studies suggest neutral mismatch repair function (Jia et al., 2020); Observed in zero breast cancer cases and one control individual (Dorling et al., 2021); This variant is associated with the following publications: (PMID: 18822302, 21120944, 31391288, 33357406, 33471991) -
The MSH2 c.89C>T (p.Pro30Leu) variant has been reported in the published literature in a healthy individual during a breast cancer association study (PMID: 33471991 (2021) see also LOVD (https://databases.lovd.nl/shared/variants/MSH2)). An experimental study characterizes the variant as having a neutral impact on mismatch repair ability (PMID: 33357406 (2021)), however additional studies are needed to determine the global effect of this variant on MSH6 protein function. The frequency of this variant in the general population, 0.0000046 (1/219710 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded conflicting predictions that this variant is deleterious or benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
Hereditary cancer-predisposing syndrome Uncertain:1Benign:1
This missense variant replaces proline with leucine at codon 30 of the MSH2 protein. Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with MSH2-related disorders in the literature. This variant has been identified in 1/219710 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
not specified Uncertain:1
Variant summary: MSH2 c.89C>T (p.Pro30Leu) results in a non-conservative amino acid change located in the DNA mismatch repair protein MutS-like, N-terminal domain (IPR007695) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 4.6e-06 in 219710 control chromosomes. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.89C>T has been reported in the literature as a VUS in at-least one individual within a cohort of 4852 patients with cancer who underwent germline multigene panel testing during 20122016 and 708 patients with cancer who underwent paired tumour and germline testing with TumorNext-Lynch (TNL) during 20172018 (Li_2020). These report(s) do not provide unequivocal conclusions about association of the variant with Lynch Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Five clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation (VUS, n=4; likely benign, n=1). Based on the evidence outlined above, the variant was classified as uncertain significance. -
Lynch syndrome Uncertain:1
- -
Hereditary nonpolyposis colorectal neoplasms Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at